AGM
CVAC

Alpine Global Management’s CureVac CVAC Stock Holding History

Alpine Global Management’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,546
Closed -$82K – 218
2022
Q4 		$82K Buy
+13,546
New +$100K 0.03% 352
2022
Q1 		– Sell
-23,033
Closed -$790K – 511
2021
Q4 		$790K Buy
+23,033
New +$927K 0.12% 185

Other funds holding CVAC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Alpine Global Management's CVAC Position: Q1 2023 in Review

Alpine Global Management sold out of CureVac (CVAC) in Q1 2023, closing a stake of 13,546 shares — an estimated $82K sold.

Alpine Global Management first reported a position in CVAC in Q4 2021 and held it in 2 quarters. The position peaked at $790K in Q4 2021. 82 funds tracked by Wall St. Rank hold CVAC as of Q1 2023.

  • Alpine Global Management reported no remaining CureVac position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 13,546 CureVac shares in Q1 2023, an estimated $82K.
  • Alpine Global Management first reported a position in CureVac in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's CureVac position peaked at $790K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held CureVac as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.